Abstract
Background The appropriateness of continuation of antiplatelet therapy in older hypertensive aspirin users with documented peptic ulcer disease (PUD) is uncertain.
Methods This multicenter cohort study screened adults aged 65 years or older, using aspirin for primary and secondary cardiovascular disease prevention between January 2014 and December 2018. Patients with panendoscopy-proven PUD and hypertension were identified. Subsequent antiplatelet strategies were categorized as aspirin discontinuation (AD), aspirin continuation (AC), and switch to clopidogrel (SC) groups. Inverse probability of treatment weighting was applied to balance baseline characteristics. The main outcomes were incident major adverse cardiac events (MACEs) and hospitalizations for upper gastrointestinal bleeding (UGIB), followed through 31 December 2020.
Results 735 eligible patients were analyzed. During a median follow-up of 39.7 months, 178 MACEs occurred. Compared with AD, SC was not related to the risk of incident MACEs, but AC increased the risk of incident MACEs (adjusted HR, 1.58; 95% CI, 1.04-2.38) in secondary prevention patients. On the other hand, 102 hospitalizations for UGIB occurred during a median follow-up of 43.4 months. Compared with AD, neither AC nor SC affected the risk of hospitalization for UGIB in secondary prevention patients. However, secondary prevention patients with chronic kidney disease were at increased risk of hospitalizations for UGIB (adjusted HR, 2.41; 95% CI, 1.30-4.47).
Conclusions AC may increase the risk of incident MACEs in older hypertensive adults with PUD previously taking aspirin for secondary cardiovascular disease prevention. The appropriateness of antiplatelet therapy continuation after PUD is diagnosed in older hypertensive adults warrants rigorous considerations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from National Science and Technology Council, National Taiwan University Hospital Hsin-Chu Branch, National Taiwan University College of Medicine, and National Taiwan University Hospital.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the NTUH Research Ethics Committee (201907023RINA), and the requirement of informed patient consent was waived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data not available due to ethical and legal restrictions of the NTUH-Integrative Medical Database.
